This is a preview of subscription content, log in via an institution to check access.
Notes
hormone receptor-positive/human epidermal growth factor receptor 2-negative
Reference
Clark MJ, et al. Cost effectiveness analysis of Oncotype DX testing in patients with synchronous unilateral primary breast cancer. 54th Annual Meeting of the American Society of Clinical Oncology : abstr. e12555, 1 Jun 2018. Available from: URL: http://abstracts.asco.org/214/AbstView_214_223189.html
Rights and permissions
About this article
Cite this article
Oncotype DX testing of ≥2 tumours not cost effective. PharmacoEcon Outcomes News 806, 20 (2018). https://doi.org/10.1007/s40274-018-5063-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5063-3